Your session is about to expire
← Back to Search
GC4711 + SBRT for Pancreatic Cancer
Study Summary
This trial is testing if adding GC4711 to SBRT (a cancer treatment) after chemotherapy can help patients with unresectable or borderline resectable nonmetastatic cancer.
- Stereotactic Body Radiation Therapy
- Pancreatic Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a stomach or small intestine ulcer that is not under control within the last 30 days.You have been diagnosed with pancreatic cancer confirmed by a tissue sample or, if not possible, by a fluid sample.You are able to perform daily activities without being limited by your health.Your organs are working properly.The tumor is clearly invading the inside of the bowel or stomach, as seen during an endoscopy.You have a type of cancer that is not prostate cancer and it is not under control.You have been diagnosed with advanced stage of cancer that has spread to other parts of the body.You have not received certain types of chemotherapy as your first treatment for the condition.You have received significant radiation treatment in your abdomen in the past.A CT scan has shown that the cancer has not spread to other parts of the body.You have been diagnosed with prostate cancer that has not spread to other parts of the body, and a tumor board has determined that you can receive a type of radiation treatment called SBRT.You have finished at least 6 weeks of specific chemotherapy treatments before starting a type of radiation therapy called SBRT.You have not fully recovered from side effects caused by previous treatments.
- Group 1: Arm A Active GC4711
- Group 2: Arm B Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are recruits still being taken in for this research trial?
"Indeed, clinicaltrials.gov's records affirm that this trial is actively enrolling participants. It was initially posted on May 7th 2021 and the last update happened November 10th 2022. The study requires 160 volunteers to be recruited from 22 different locations."
Has the Food and Drug Administration officially recognized GC4711 as a viable pharmaceutical?
"With a score of 2, our team at Power acknowledges that Drug GC4711 has some evidence backing its safety profile; however, no clinical data currently exists to validate the efficacy of this experimental medication."
How many participants are enrolled in this clinical experiment?
"Agreed. The details published on clinicaltrials.gov demonstrate that this study, which was originally unveiled on May 7th 2021, is actively recruiting participants from 22 different medical centres with a total goal of 160 patients."
Where are the sites hosting this clinical research?
"At present, there are 22 recruitment sites for the trial. These include locations such as Austin and University Park in addition to other locales. To minimise travel demands, it is wise to select a site closest to where you reside."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger